We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

In the past year, there was news about the prevention of progression to diabetes with tirzepatide (Mounjaro/Zepbound, Eli Lilly), benefits of tirzepatide and semaglutide (Ozempic/Wegovy ...

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

One investor and three analysts told Reuters they expect Lilly to share details on how it plans to promote Zepbound this year in a bid to take more market share from Wegovy, an older, more ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth ... the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe ...

The most prescribed OMDs were phentermine, semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound). By February 2024, phentermine, Wegovy, and Zepbound had about 0.74, 0.42 ...